Sahy

Researchers are evaluating the safety and effectiveness of TAK-279 in treating adults with moderately to severely active Crohns disease, a long-lasting condition causing inflammation in any part of the gut. This Phase 2b study aims to see if three different doses of TAK-279 can reduce bowel inflammation and ulcers compared to a placebo after 12 weeks of treatment. The study also compares medical problems experienced by participants taking TAK-279 or placebo and how well they tolerate these issues. An endoscopy will be used to assess bowel inflammation. Participants will be randomly assigned to one of four groups three groups receiving different doses of TAK-279 capsules and one group receiving placebo capsules. The treatment period lasts 52 weeks one year, followed by a 4-week safety follow-up. TAK-279 and placebo capsules are taken orally, and the study is conducted at multiple global centers. Treatment groups remain undisclosed to participants and doctors unless urgent medical needs arise. During the study, participants will visit the clinic 15 times for assessments, including endoscopies to check for bowel inflammation. Researchers will measure responses such as endoscopic improvement based on the Simple Endoscopic Score for Crohns Disease at week 12 and other clinical remission and response indicators. Quality of life and fatigue levels will also be evaluated. The total study duration is about 60 weeks, including treatment and follow-up.

Researchers are evaluating the safety and effectiveness of induction therapy using Afimkibart also called RO7790121 in people with moderately to severely active ulcerative colitis UC. This Phase III study is designed as a multicenter, double-blind, placebo-controlled trial to compare Afimkibart with a placebo. The study aims to understand how well Afimkibart works to induce remission in UC and its safety profile. Participants will be randomly assigned to one of two groups. One group will receive Afimkibart through an intravenous IV infusion followed by a subcutaneous SC injection, while the other group will receive matching placebo infusions and injections. The treatment period lasts 12 weeks, during which researchers will assess the effects of the therapies. Throughout the study, participants will undergo various assessments including evaluations of clinical remission, endoscopic improvement, histologic changes, and symptom severity at specified time points such as baseline, Week 2, and Week 12. Safety will be monitored by tracking adverse events for up to 30 weeks after starting treatment. The total participation duration spans the treatment and follow-up periods to gather comprehensive data on outcomes and safety.

Researchers are studying the safety and effectiveness of NNC0487-0111 for adults with excess body weight and type 2 diabetes. This Phase 3 clinical trial compares NNC0487-0111 with a placebo to see how well the medicine helps reduce body weight when taken along with diet and exercise changes. Participants have type 2 diabetes for at least six months and meet specific health criteria to join the study. Participants are randomly assigned to receive one of four different doses of NNC0487-0111 or a placebo. Each treatment is given as a weekly injection under the skin using a pre-filled pen injector, targeting areas like the thigh, abdomen, or upper arm. All participants follow a reduced-calorie diet and increase physical activity during the study. The main treatment period lasts 84 weeks, with body weight and other health measures tracked throughout. During the study, participants will have regular assessments including blood tests to check blood sugar levels, cholesterol, and other health markers. Researchers will also monitor waist size, blood pressure, and quality of life related to physical function. Safety is carefully watched by tracking any side effects or adverse events until 88 weeks. Overall, participants are involved in frequent visits and health evaluations to measure treatment impact and safety over nearly two years.

Researchers are evaluating the safety and effectiveness of LY4268989 compared to a placebo in adults with moderately to severely active ulcerative colitis UC. The study focuses on participants with a diagnosis of UC for at least 3 months, confirmed by specific clinical and endoscopic criteria. This Phase 2 trial aims to better understand how LY4268989 may impact clinical remission and response in this patient group over a long-term period. Participants will receive either one of two doses of LY4268989 or a placebo, all administered orally. The study is randomized and double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. The treatment period lasts up to approximately 108 weeks, excluding the screening phase, allowing for assessment of the drug over an extended time. During the study, participants will undergo regular evaluations including clinical assessments using the Modified Mayo Score to measure remission and response at multiple time points, including weeks 10 and 52. Researchers will also monitor symptomatic response and measure plasma concentrations of LY4268989. Safety and effectiveness will be tracked through these clinical and laboratory tests to understand the drugs impact on UC over the study duration.